Calyx Operating Subsidiary Participates in Canada's First Bio-Fuel Powered Revenue Flight


VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 17, 2012) - Calyx Bio-Ventures Inc. ("Calyx" or the "Company") (TSX VENTURE:CYX) is pleased to announce that the Company's operating subsidiary, Agrisoma Biosciences Inc. ("Agrisoma"), produced the carinata bio-fuel which was blended into the fuel used in Canada's first bio-fuel powered revenue flight, successfully conducted today by Porter Airlines.

In the successful conclusion to a test program that was launched in 2010, Porter Airlines flew one of its Bombardier Q400 turboprops from its base at Billy Bishop Toronto City Airport to Ottawa using a 50/50 blend of biofuel and Jet A1 fuel in one of its engines. The fuel was certified to the new American Society for Testing and Materials (ASTM) D7566/D1655 standard and the biofuel used was derived from the oilseed crops, Camelina sativa* (49 per cent) and Brassica carinata* (one per cent). The aircraft's other engine was powered by Jet A1 fuel. The flight included passengers making their way to Ottawa for business and pleasure, representatives from the biofuel test program's partnering organizations and media.

This is the final step in a two-year project whose key members are Targeted Growth, Bombardier Aerospace, Pratt and Whitney Canada, the manufacturer of the PW150A engines that power the Q400 aircraft, and Porter Airlines. Funding for the biofuel test program was provided by the key partners, as well as by Business-Led Networks of Centres of Excellence (BL-NCE) through the Green Aviation Research & Development Network (GARDN).

Additional support to the program was provided by Agrisoma Biosciences Inc., which grew the carinata and produced the carinata bio-oil; Sustainable Oils, which crushed the camelina to make the camelina bio-oil; Honeywell UOP, which converted the bio-oils into the bio-derived jet fuel to meet the D7566 standard; and SkyNRG who were responsible for logistics and blending meeting the D1655 specification.

"We are very pleased that Agrisoma was a participant in supplying bio-fuel refined from Agrisoma's proprietary carinata for this flight," commented Hugh Notman, President and Chief Executive Officer of Calyx. "We believe this demonstrates carinata's potential to produce a high quality fuel that performs well in a commercial setting."

On February 9, 2012, in preparation for Porter's revenue flight, Bombardier flew a Q400 turboprop test aircraft on the ASTM D7566/D1655 bio-derived jet fuel. This was the first such biofuel-powered test flight in Canada.

About Calyx

Calyx Bio-Ventures Inc. trades on the TSX Venture Exchange under the symbol "CYX" and owns approximately one third of an operating subsidiary called Agrisoma Biosciences Inc. Agrisoma is a private agricultural biotechnology company that uses a proprietary Engineered Trait Loci (ETL) technology licensed from Calyx to commercialize a suite of industry-leading oil quality and crop improvement traits for use in energy feedstock crops. For further information about Calyx, its technology, collaborations and partnerships, please visit: www.calyxbio.com.

* Camelina sativa and Brassica carinata are members of the family of flowering plants known as the Brassicaceae. The Brassicaceae also include well-known plants such as broccoli, cabbage, cauliflower and turnips.

ON BEHALF OF THE BOARD

CALYX BIO-VENTURES INC.

W. Hugh Notman, President & CEO

Forward-Looking Statements: This document contains certain forward-looking statements concerning Calyx, as well as other expectations, plans, goals, objectives, information or statements about future events, conditions, results of operations or performance that may constitute "forward-looking statements" or "forward-looking information" under applicable securities legislation. Such statements or information involve substantial known and unknown risks and uncertainties, certain of which are beyond Calyx's control, including general business, economic, competitive, political and social uncertainties; the delay or failure to receive regulatory approvals, the characteristics and viability for bio-fuel development, the willingness of third parties to conclude agreements with Calyx on terms that are acceptable to management of Calyx, and the ability of Calyx to secure sufficient future funding to carry out all of its business plans.

Such forward-looking statements or information are based on a number of assumptions which may prove to be incorrect. In addition to other assumptions identified in this news release, assumptions have been made regarding, among other things, commodity prices, operating conditions, capital and other expenditures, and project development activities.

Although Calyx believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Calyx can give no assurance that such expectations will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Calyx and described in the forward-looking statements or information.

The forward-looking statements or information contained in this news release are made as of the date hereof and Calyx undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise unless so required by applicable securities laws or the TSX Venture Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

This press release shall not constitute an offer to sell, nor the solicitation of an offer to buy, any securities in the United States, nor shall there be any sale of securities mentioned in this press release in any state in the United States in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Calyx Bio-Ventures Inc. - Corporate Inquiries
W. Hugh Notman
President & CEO
604-689-2495
hnotman@calyxbio.com

Calyx Bio-Ventures Inc. - Investor Relations
Keir Reynolds
778-998-9242
kreynolds@calyxbio.com